Jillian M Berkman1, Vihang Nakhate1, L Nicolas Gonzalez Castro2. 1. Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. 2. Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract
Background: Although rare, the co-occurrence of multiple sclerosis (MS) and glioma poses unique challenges in terms of diagnosis and management for both neurologists and neuro-oncologists. Methods: Here we report on a single-center cohort of four patients with a diagnosis of multiple sclerosis who developed gliomas. Results: Our cohort reflects the epidemiology of glioma in terms of the relative frequency of IDH-wildtype and IDH-mutant cases. The patients in 3 out of the 4 cases presented did not develop their tumors in areas of pre-existing demyelinating lesions. Conclusions: We did not find evidence to support the hypothesis that chronic gliosis from demyelinating plaques may serve as a substrate for secondary induction of a glial neoplasm. In our Discussion, we provide recommendations for distinguishing neoplastic from demyelinating lesions, review the evidence for demyelination as a risk factor for gliomagenesis, and highlight important considerations for the concurrent management of glioma and MS.
Background: Although rare, the co-occurrence of multiple sclerosis (MS) and glioma poses unique challenges in terms of diagnosis and management for both neurologists and neuro-oncologists. Methods: Here we report on a single-center cohort of four patients with a diagnosis of multiple sclerosis who developed gliomas. Results: Our cohort reflects the epidemiology of glioma in terms of the relative frequency of IDH-wildtype and IDH-mutant cases. The patients in 3 out of the 4 cases presented did not develop their tumors in areas of pre-existing demyelinating lesions. Conclusions: We did not find evidence to support the hypothesis that chronic gliosis from demyelinating plaques may serve as a substrate for secondary induction of a glial neoplasm. In our Discussion, we provide recommendations for distinguishing neoplastic from demyelinating lesions, review the evidence for demyelination as a risk factor for gliomagenesis, and highlight important considerations for the concurrent management of glioma and MS.
Authors: A M Menzies; D B Johnson; S Ramanujam; V G Atkinson; A N M Wong; J J Park; J L McQuade; A N Shoushtari; K K Tsai; Z Eroglu; O Klein; J C Hassel; J A Sosman; A Guminski; R J Sullivan; A Ribas; M S Carlino; M A Davies; S K Sandhu; G V Long Journal: Ann Oncol Date: 2017-02-01 Impact factor: 32.976
Authors: Giulia C Leonardi; Justin F Gainor; Mehmet Altan; Sasha Kravets; Suzanne E Dahlberg; Lydia Gedmintas; Roxana Azimi; Hira Rizvi; Jonathan W Riess; Matthew D Hellmann; Mark M Awad Journal: J Clin Oncol Date: 2018-05-10 Impact factor: 44.544
Authors: Alexandra M Miller; Ronak H Shah; Elena I Pentsova; Maryam Pourmaleki; Samuel Briggs; Natalie Distefano; Youyun Zheng; Anna Skakodub; Smrutiben A Mehta; Carl Campos; Wan-Ying Hsieh; S Duygu Selcuklu; Lilan Ling; Fanli Meng; Xiaohong Jing; Aliaksandra Samoila; Tejus A Bale; Dana W Y Tsui; Christian Grommes; Agnes Viale; Mark M Souweidane; Viviane Tabar; Cameron W Brennan; Anne S Reiner; Marc Rosenblum; Katherine S Panageas; Lisa M DeAngelis; Robert J Young; Michael F Berger; Ingo K Mellinghoff Journal: Nature Date: 2019-01-23 Impact factor: 49.962